Yuan G. Hu
277 Yanta West Road
Xi'an, 710061, China
Xi'an, 710061, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
MetaDetection: wireless intelligent detection of multiliquids by using space-time-coding metasurface.
Journal: National science review
Published: March 04, 2025
Polypyrrole-Coated Mesoporous TiO2 Nanocomposites Simultaneously Loading DOX and Aspirin Prodrugs for a Synergistic Theranostic and Anti-Inflammatory Effect.
Journal: ACS applied bio materials
Published: January 11, 2022
Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Journal: World journal of gastrointestinal oncology
Published: December 31, 2021
Inhibition of Ras protein activator like 2 produces antitumor effects in gastric cancer via the suppression of YAP1 activation.
Journal: Environmental toxicology
Published: June 25, 2021
Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways.
Journal: Translational cancer research
Published: January 31, 2021
Thrombospondin 4/integrin α2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 17, 2020
The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Journal: Annals of clinical and laboratory science
Published: September 01, 2019
α-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.
Journal: Journal of cellular and molecular medicine
Published: July 27, 2019
Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells.
Journal: Journal of Cancer
Published: January 02, 2019
Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Journal: Cancer biology & therapy
Published: November 22, 2018
Artificial Neural Networking Model for the Prediction of Early Occlusion of Bilateral Plastic Stent Placement for Inoperable Hilar Cholangiocarcinoma.
Journal: Surgical laparoscopy, endoscopy & percutaneous techniques
Published: December 19, 2017
Last Updated: 09/26/2026